Antibody-drug conjugate news and latest updates

Home Antibody-drug conjugates Page 2

Latest Posts

News and Trends 31 Jan 2023

BiVictriX announces positive data from leukemia study

BiVictriX Therapeutics plc has announced positive in vivo data from a toxicity evaluation study with BVX001, the company’s lead program, compared to gemtuzumab ozogamicin (GO). GO, marketed as Mylotarg, is…

January 31, 2023 - 3 minutesmins - By Jim Cornall

antibody drug conjugate adc small cancer treatment

News and Trends 12 Jan 2023

Ajinomoto and Exelixis to discover and develop novel ADCs to treat cancer

Ajinomoto Co., Inc. has signed a license agreement with Exelixis, Inc. to incorporate AJICAP, Ajinomoto Co.'s proprietary site-specific bioconjugation and linker technologies, in the development of some of Exelixis' antibody-drug…

January 12, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 5 Jan 2023

Hummingbird Bioscience and Synaffix to develop ADC program

Synaffix B.V. and Hummingbird Bioscience have entered into a licensing agreement that will enable Hummingbird Bio to develop a next generation antibody drug conjugate (ADC) program using Synaffix technology. Synaffix…

January 5, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Dec 2022

Mersana Therapeutics and Merck to develop novel ADCs

Mersana Therapeutics, Inc. has announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA, Darmstadt, Germany to discover novel Immunosynthen antibody drug conjugates (ADCs) directed against…

December 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Dec 2022

Merck and Kelun-Biotech collaborating on seven ADC cancer candidates

Merck (MSD outside of the U.S. and Canada), and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd), have entered into an exclusive license and collaboration agreement to develop…

December 23, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 21 Dec 2022

Watch: Araris Biotech at Bio-Europe

Araris Biotech AG is a Swiss-headquartered company pioneering the development of its novel antibody-drug-conjugate (ADC)-linker technology to enable efficient and precise production of ADCs. Its linker platform enables the attachment…

December 21, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 15 Dec 2022

Solve Therapeutics launches to tackle cancer

Solve Therapeutics, Inc. (SolveTx), an oncology-focused biopharmaceutical company, has launched with the mission of developing novel antibody-based therapies targeting tumor-specific antigens. The company's formation reunites the former VelosBio Inc. team.…

December 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 9 Dec 2022

Actinium Pharmaceuticals and Columbia University to study Actimab-A in AML patients

Actinium Pharmaceuticals, Inc. has entered into a research collaboration with Columbia University to study Actimab-A, its clinical-stage CD33 targeting radiotherapeutic, with engineered hematopoietic stem cells (eHSCs) modified by CRISPR/Cas9 gene…

December 9, 2022 - 4 minutesmins - By Jim Cornall

More News! 8 Dec 2022

Enhertu’s positive results demonstrate improvement in overall survival

Enhertu, an antibody drug conjugate, being jointly developed by Daiichi Sankyo and AstraZeneca, has demonstrated a statistically significant and clinically meaningful improvement in overall survival. Updated results from DESTINY-Breast03 phase…

December 8, 2022 - 4 minutesmins - By Liza Laws

News and Trends 7 Dec 2022

BiVictriX identifies development lead for ADC cancer program

BiVictriX Therapeutics plc, an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, has identified a development lead for…

December 7, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 30 Nov 2022

SOTIO exercises option on ADC program

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, has exercised its first of five exclusive, target-specific options with LegoChem Biosciences (LCB) for antibody-drug conjugate (ADC) SOT106, which…

November 30, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 18 Nov 2022

AstraZeneca and Daiichi Sankyo’s Enhertu recommended for approval

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) for patients previously treated HER-2 positive advanced gastric cancer. The drug is also used for gastroesophageal junction…

November 18, 2022 - 3 minutesmins - By Liza Laws

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Partner with world-leading academics working on sustainable materials R&D

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering